SOUTH SAN FRANCISCO, Calif.,
Feb. 21, 2019 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that it will report its fourth quarter and year end 2018
financial results after market close on Thursday, February 28, 2019. Rigel senior
management will follow the announcement with a live conference call
and webcast at 5:00pm Eastern Time
(2:00pm Pacific Time) to discuss the
financial results and give a company update.
Participants can access the live conference call by dialing
(855) 892-1489 (domestic) or (720) 634-2939 (international) and
using the Conference ID number 2257425. The conference call
will also be webcast live and can be accessed from Rigel's website
at www.rigel.com. The webcast will be archived and
available for replay for 30 days after the call via the Rigel
website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated
to discovering, developing and providing novel small molecule drugs
that significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is TAVALISSE®
(fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase
(SYK) inhibitor, for the treatment of adult patients with chronic
immune thrombocytopenia who have had an insufficient response to a
previous treatment. Rigel's current clinical programs include an
upcoming Phase 3 study of fostamatinib in autoimmune hemolytic
anemia and an ongoing Phase 1 study of R835, a proprietary molecule
from its interleukin receptor associated kinase (IRAK) program. In
addition, Rigel has product candidates in clinical development with
partners BerGenBio ASA, Daiichi Sankyo, Aclaris Therapeutics, and
AstraZeneca.
Please see www.TAVALISSE.com for the full Prescribing
Information.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
Media Contact: Jessica Daitch
Phone: 917.816.6712
Email: jessica.daitch@syneoshealth.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-financial-results-300799456.html
SOURCE Rigel Pharmaceuticals, Inc.